Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: A matched analysis

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 8, 2011, Pages 838-848

  Leombruno, John Paul ^a   Nguyen, Geoffrey C ^a,b   Grootendorst, Paul ^a,c   Juurlink, David ^a   Einarson, Tom ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Crohn's disease; Hospitalization; Infliximab; Propensity score; Surgery

Indexed keywords

INFLIXIMAB;

ABDOMINAL SURGERY; ADULT; ALGORITHM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUEBEC;

EID: 79960746475     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2132     Document Type: Article

References (51)

1. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000; 95(8): 1955-1960.
2. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol 2004; 99(4): 650-655.
3. Longobardi T, Bernstein CN. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(6): 731-743.
4. Longobardi T, Bernstein CN. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol 2007; 102(8): 1683-1691.
5. Agrez MV, Valente RM, Pierce W, Melton LJ, III, van Heerden JA, Beart RW, Jr. Surgical history of Crohn's disease in a well-defined population. Mayo Clin Proc 1982; 57(12): 747-752.
6. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 2000; 87(12): 1697-1701.
7. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26(2): 146-150.
8. Lapidus A, Bernell O, Hellers G, Lofberg R. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114(6): 1151-1160.
9. Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117(1): 49-57.
10. Andrews HA, Lewis P, Allan RN. Prognosis after surgery for colonic Crohn's disease. Br J Surg 1989; 76(11): 1184-1190.
11. Kim NK, Senagore AJ, Luchtefeld MA et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997; 63(7): 627-633.
12. Mekhjian HS, Switz DM, Watts HD, Deren JJ, Katon RM, Beman FM. National cooperative Crohn's disease study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979; 77(4 Pt 2): 907-913.
13. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. experience with 1379 patients. Ann Surg 1991; 214(3): 230-238.
14. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 1985; 88(6): 1826-1833.
15. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53(10): 1471-1478.
16. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95(3): 677-683.
17. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002; 20(10): 639-652.
18. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14(4): 318-327.
19. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 24(2): 319-328.
20. Caprilli R, Gassull MA, Escher JC et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55(Suppl 1): i36-i58.
21. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54(2): 237-241.
22. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128(4): 862-869.
23. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126(2): 402-413.
24. Jewell DP, Satsangi J, Lobo A et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17(10): 1047-1052.
25. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002; 35(2): 151-156.
26. Saro C, da la CC, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007; 26(10): 1313-1323.
27. Taxonera C, Rodrigo L, Casellas F et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009; 43(10): 950-956.
28. Azoulay L, Blais L, Koren G, LeLorier J, Berard A. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008; 69(4): 526-532.
29. Charbonneau C, Massoud F, Dorais M, LeLorier J. A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes. Curr Med Res Opin 2008; 24(12): 3287-3294.
30. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008; 178(4): 413-420.
31. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149(10): 916-924.
32. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79(387): 516-524.
33. Bryson A, Dorsett R, Purdon S. The use of propensity score matching in the evaluation of labour market policies. Working Paper 4. 2002. Policy Studies Institute and National Centre for Social Research.
34. Caliendo M, Kopeinig S. Some practical guidance for the implementation of propensity score matching. J Econ Surv 2008; 22(1): 31-72.
35. D'Agostino RB, Rubin DB. Estimating and using propensity scores with partially missing data. J Am Stat Assoc 2000; 95(451): 749-759.
36. Perkins SM, Tu W, Underhill MG, Zhou XH, Murray MD. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000; 9(2): 93-101.
37. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41-55.
38. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996; 52(1): 249-264.
39. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2): 757-763.
40. Shrier I, Platt RW, Steele RJ. Re: "variable selection for propensity score models". Am J Epidemiol 2007; 166(2): 238-239.
41. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13(12): 841-853.
42. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26(4): 734-753.
43. Heckman J, Smith JA, Clements N. Making the most out of programme evaluations and social experiments: accounting for heterogeneity in programme impacts. Rev Econ Stud 1997; 64(4): 487-537.
44. Juurlink D, Preyra C, Croxford R et al. Canadian institute for health information discharge abstract database: a validation study, Institute for Clinical Evaluative Sciences:Toronto, ON, 2006.
45. Pinner RW, Teutsch SM, Simonsen L et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275(3): 189-193.
46. Wilson D, Bhopal R. Impact of infection on mortality and hospitalization in the north east of England. J Public Health Med 1998; 20(4): 386-395.
47. Lu TH. Don't overlook infectious diseases in ICD-9 chapters other than chapter I. Int J Infect Dis 2005; 9(3): 180-181.
48. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 2008; 17(12): 1218-1225.
49. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-1549.
50. Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007; 13(12): 1529-1535.
51. Crohn's and Colitis Foundation of Canada. The Burden of Inflammatory Bowel Disease (IBD) in Canada. Toronto, 13 Sep 2009.